A groundbreaking new study has unveiled significant barriers that impede the efficient execution of multinational randomized clinical trials across Europe, with far-reaching implications for the future of global health emergencies. Spearheaded by a collaborative team of researchers from the Netherlands, the United Kingdom, and other parts of Europe, this investigation offers an unprecedented quantification of the ethical, administrative, regulatory, and logistical (EARL) obstacles that challenge the smooth operation of large-scale international platform trials. The findings highlight an urgent need to overhaul existing frameworks to better prepare for imminent public health crises on a global scale.
Randomized controlled trials (RCTs) remain the gold standard for generating robust evidence that guides medical practice worldwide. Yet, the operational complexity inherent in these trials often proves daunting, especially when conducted across multiple countries with diverse regulatory landscapes. The EARL components—encompassing ethical approvals, administrative contracts, regulatory permissions, and logistical coordination—pose substantial challenges, slowing down trial initiation and complicating patient enrollment. The recent COVID-19 pandemic starkly exposed these systemic inefficiencies, demonstrating vast inter-country discrepancies in research readiness and responsiveness during a critical window for rapid intervention.
The study meticulously analyzed data from the Randomized Embedded Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP), a pioneering international trial designed to evaluate multiple therapeutic agents for pneumonia, including COVID-19 treatments. REMAP-CAP’s adaptive platform design allowed the investigators to examine procedural timelines across 19 European countries spanning pre-pandemic (2016-2020) and pandemic (2020-2023) periods. This comprehensive dataset included 257 fully executed contracts with clinical sites, providing a unique opportunity to dissect and compare the numerous stages involved in trial setup across diverse regulatory and institutional contexts.
By focusing on three critical metrics—the time to finalize site contracts, the duration until ethical and regulatory approvals (TTA), and the interval to first patient enrollment (FPI)—the study revealed stark contrasts in efficiency that directly impact the rapid deployment of clinical research. The United Kingdom stood out prominently, demonstrating remarkable improvements during the pandemic, with median contract completion times plummeting by an astounding 97 percent, from nearly 200 days to just five. In comparison, other European countries witnessed only modest progress, with median contract times reducing by approximately 18 percent.
Ethical and regulatory approval timelines further accentuated these disparities. The UK streamlined its processes to achieve median pre-approval durations of merely eight days during the pandemic, in sharp contrast to a median of 115 days observed elsewhere in Europe. Such delays, compounded by protracted contract negotiations and variable site engagement, culminated in a significantly accelerated time from approval to first patient enrollment in the UK—averaging 26 days, compared to an elongated 116 days in other nations. These variances underscore profound structural and procedural differences that undermine the uniformity and predictability of multinational clinical trials.
The implications of these findings are profound. As emphasized by Denise van Hout, MD, PhD, the study’s lead author and epidemiologist at UMC Utrecht, the complexity and heterogeneity of EARL procedures constitute a formidable bottleneck that hampers timely trial initiation and compromises patient access to potentially lifesaving interventions. The urgent call to action involves not only policymakers and regulators but also the scientific community, legal experts, and trial sponsors, who must collectively drive reforms toward harmonized, transparent, and streamlined workflows.
Central to this transformation is the recognition that the UK’s relative success during the pandemic was buoyed by pre-existing research networks and emergency response frameworks, which facilitated rapid regulatory adaptations and efficient operational coordination. In contrast, other European nations struggled with fragmented governance, inconsistent interpretations of guidelines, and laborious contract negotiations. The absence of a unified European strategy for EARL protocols during emergencies reveals a critical vulnerability in the continent’s research ecosystem.
The pathway forward necessitates the establishment of consistent, scalable processes that maintain rigorous ethical standards without compromising the urgency of trial delivery. Such improvements might include standardized templates for contracts, centralized ethical review boards, and synchronized regulatory pathways that reduce redundancy and accelerate decision timelines. Moreover, fostering proactive engagement with ethics committees and regulatory bodies early in the trial design phase can preempt delays and align expectations across stakeholders.
Addressing logistical hurdles is equally pivotal. Efficient coordination among multinational sites requires investment in digital infrastructures, enhanced communication channels, and trained personnel adept in navigating diverse regulatory environments. Leveraging adaptive platform trial designs, as exemplified by REMAP-CAP, allows real-time learning and rapid modification of trial arms, but these benefits are contingent upon overcoming EARL delays that currently impede operational agility.
The study’s comprehensive quantification of delays enriches the discourse on clinical trial governance, providing hard data to inform policy interventions aimed at reinforcing Europe’s preparedness for future pandemics. Beyond Europe, the lessons hold global relevance, as many regions confront similar challenges in harmonizing clinical research protocols across jurisdictional boundaries. Prioritizing these reforms will catalyze not only accelerated scientific discovery but also equitable, timely patient access to innovative therapies.
In summation, this pioneering analysis exposes the critical choke points that stunt the efficient delivery of multinational randomized clinical trials. The juxtaposition of the UK’s rapid response capabilities against the protracted timelines in other European countries serves as a clarion call for policy harmonization and infrastructural investment. As global health threats continue to emerge unpredictably, the imperative to refine EARL procedures grows ever more urgent, demanding concerted efforts to bridge regulatory gaps and dismantle administrative inertia threatening to delay vital medical breakthroughs.
The work by van Hout and colleagues thus represents a landmark contribution to the field of clinical research management, offering actionable insights into the intricate interplay between ethics, regulation, administration, and logistics in the context of multinational clinical trials. The study’s findings not only map the current state but also chart a course for transformative change, underscoring the vital need for collaboration across sectors to ensure that clinical trials can swiftly respond to emergent health crises without compromising ethical integrity or scientific rigor.
Subject of Research: People
Article Title: Hurdles for Delivery of Multinational Randomized Clinical Trials
News Publication Date: 2-Jul-2025
Web References:
- REMAP-CAP official site: http://www.remapcap.eu/
- Article DOI: https://doi.org/10.1001/jamanetworkopen.2025.18503
References:
Van Hout D, Mouncey P, Harrison D, Bonten M, Derde L, and the REMAP-CAP European Regional Investigators. Hurdles for the Delivery of Multinational Randomized Clinical Trials. JAMA Network Open, July 2, 2025. https://doi.org/10.1001/jamanetworkopen.2025.18503
Image Credits:
Credit: Denise van Hout, MD PhD
Keywords:
Clinical trials, Clinical studies, Research ethics, Legislation, Regulatory affairs, Research management, Biomedical policy, Regulatory policy, Ethics, Medical ethics, Epidemics, Drug studies, Drug therapy
